Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
A Stock Forecast 2025-2026
$146.82
Current Price
$41.62B
Market Cap
Buy 10
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to A Price Targets
+15.8%
To High Target of $170.00
+2.8%
To Median Target of $151.00
-11.5%
To Low Target of $130.00
A Price Momentum
+0.1%
1 Week Change
+5.1%
1 Month Change
+15.5%
1 Year Change
+9.3%
Year-to-Date Change
-4.6%
From 52W High of $153.84
+52.3%
From 52W Low of $96.43
📊 TOP ANALYST CALLS
Did A Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Agilent is one of their latest high-conviction picks.
Latest A Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, A has a bullish consensus with a median price target of $151.00 (ranging from $130.00 to $170.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $146.82, the median forecast implies a 2.8% upside. This outlook is supported by 10 Buy, 8 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Dan Leonard at UBS, projecting a 15.8% upside. Conversely, the most conservative target is provided by Vijay Kumar at Evercore ISI Group, suggesting a 11.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
A Analyst Ratings
10
Buy
8
Hold
0
Sell
A Price Target Range
Low
$130.00
Average
$151.00
High
$170.00
Current: $146.82
Latest A Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for A.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 14, 2025 | TD Cowen | Dan Brennan | Buy | Maintains | $162.00 |
| Oct 9, 2025 | JP Morgan | Casey Woodring | Overweight | Maintains | $165.00 |
| Oct 8, 2025 | UBS | Dan Leonard | Buy | Upgrade | $170.00 |
| Oct 8, 2025 | Rothschild & Co | Natalya Davies | Buy | Initiates | $165.00 |
| Oct 7, 2025 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $140.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $145.00 |
| Sep 15, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $150.00 |
| Aug 29, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $125.00 |
| Aug 28, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $142.00 |
| Aug 28, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $140.00 |
| Aug 28, 2025 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $128.00 |
| Jul 8, 2025 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $130.00 |
| Jun 24, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $125.00 |
| Jun 24, 2025 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| May 29, 2025 | UBS | Elizabeth Garcia | Neutral | Maintains | $130.00 |
| May 29, 2025 | JP Morgan | Tycho Peterson | Overweight | Maintains | $155.00 |
| May 22, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $140.00 |
| Apr 21, 2025 | Jefferies | Brandon Couillard | Hold | Maintains | $116.00 |
| Apr 17, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $135.00 |
| Apr 16, 2025 | Bernstein | Market Perform | Maintains | $N/A |
Agilent Technologies Inc. (A) Competitors
The following stocks are similar to Agilent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Agilent Technologies Inc. (A) Financial Data
Agilent Technologies Inc. has a market capitalization of $41.62B with a P/E ratio of 34.4x. The company generates $6.79B in trailing twelve-month revenue with a 18.0% profit margin.
Revenue growth is +10.1% quarter-over-quarter, while maintaining an operating margin of +23.2% and return on equity of +19.9%.
Valuation Metrics
Market Cap
$41.62B
Enterprise Value
$43.70B
P/E Ratio
34.4x
PEG Ratio
1.6x
Price/Sales
6.1x
Growth & Margins
Revenue Growth (YoY)
+10.1%
Gross Margin
+51.1%
Operating Margin
+23.2%
Net Margin
+18.0%
EPS Growth
+19.1%
Financial Health
Cash/Price Ratio
+3.7%
Current Ratio
2.2x
Debt/Equity
56.4x
ROE
+19.9%
ROA
+8.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Agilent Technologies Inc. (A) Business Model
About Agilent Technologies Inc.
What They Do
Provides analytical instruments and services for life sciences.
Business Model
Agilent Technologies generates revenue by offering a wide range of analytical instruments, software, services, consumables, and reagents tailored for life sciences, diagnostics, and applied chemical markets. The company primarily serves pharmaceutical, biotechnology, and government laboratories, facilitating research and development processes.
Additional Information
Founded in 1999 as a spin-off from Hewlett-Packard, Agilent has a strong focus on innovation, particularly in genomics, proteomics, and metabolomics. Its contributions to health, safety, and environmental analysis highlight its vital role in scientific research and public health initiatives globally.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
18,000
CEO
Mr. Padraig McDonnell
Country
United States
IPO Year
1999
Website
www.agilent.comAgilent Technologies Inc. (A) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -70.15% and -23.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 14, 2025
By Zacks Equity Research
Tale of the Tape
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Lags Revenue Estimates
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of 0.00% and -0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 13, 2025
By Zacks Equity Research
Tale of the Tape
MacroGenics (MGNX) Q3 Earnings and Revenues Surpass Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of +156.25% and +157.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 12, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Agilent Technologies awarded UC Davis Professor Marie Heffern an ARC award for her research on peptide and protein therapeutics aimed at treating diabetes and obesity.
Why It Matters
Agilent's ARC award highlights its commitment to innovation in biotech, potentially enhancing its market position in the growing diabetes and obesity therapeutics sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Agilent Technologies Inc. (NYSE: A) will announce Q4 fiscal 2025 results on Nov. 24 post-market. A conference call is scheduled for 1:30 p.m. PST the same day, with a recording available for 90 days.
Why It Matters
Agilent's upcoming Q4 earnings release and conference call are key for assessing its financial health and future performance, influencing stock price and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Agilent Technologies Inc. has appointed Adam S. Elinoff as CFO, effective Nov. 17. He has 20 years of financial experience and previously worked at Amgen.
Why It Matters
Agilent Technologies' new CFO, Adam S. Elinoff, has a strong track record in financial operations and transformation, indicating potential for improved financial performance and strategic growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Citi analysts report a positive meeting with Agilent Technologies' management, highlighting growth drivers expected to enhance earnings leverage in the coming year.
Why It Matters
Citi's positive outlook on Agilent's growth drivers suggests potential earnings growth, which could boost investor confidence and influence stock performance.
Source: Proactive Investors
Market Sentiment:
Positive
Agilent Introduces the Altura Line of Inert HPLC Columns for Superior Results in Biotherapeutic Testing
1 month ago
Quick Summary
Agilent Technologies launched new Altura Ultra Inert HPLC Columns, enhancing liquid chromatography for biotherapeutics, including peptide GLP-1 and oligonucleotide therapies.
Why It Matters
Agilent's new HPLC columns enhance performance in biotherapeutics, likely boosting demand and market share in a growing sector, which can positively impact revenue and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Agilent Announces New Insight Series Alarm Resolution Systems for Airport Security Screening
1 month ago
Quick Summary
Agilent Technologies Inc. launched the Insight Series Alarm Resolution Systems, including the Insight300M and InsightBLS, for enhanced airport security with low false alarm rates and compliance with global regulations.
Why It Matters
Agilent Technologies' launch of advanced security systems positions the company to capture market share in airport security, potentially boosting revenue and enhancing investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About A Stock
What is Agilent Technologies Inc.'s (A) stock forecast for 2026?
Based on our analysis of 26 Wall Street analysts, Agilent Technologies Inc. (A) has a median price target of $151.00. The highest price target is $170.00 and the lowest is $130.00.
Is A stock a good investment in 2026?
According to current analyst ratings, A has 10 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $146.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for A stock?
Wall Street analysts predict A stock could reach $151.00 in the next 12 months. This represents a 2.8% increase from the current price of $146.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Agilent Technologies Inc.'s business model?
Agilent Technologies generates revenue by offering a wide range of analytical instruments, software, services, consumables, and reagents tailored for life sciences, diagnostics, and applied chemical markets. The company primarily serves pharmaceutical, biotechnology, and government laboratories, facilitating research and development processes.
What is the highest forecasted price for A Agilent Technologies Inc.?
The highest price target for A is $170.00 from Dan Leonard at UBS, which represents a 15.8% increase from the current price of $146.82.
What is the lowest forecasted price for A Agilent Technologies Inc.?
The lowest price target for A is $130.00 from Vijay Kumar at Evercore ISI Group, which represents a -11.5% decrease from the current price of $146.82.
What is the overall A consensus from analysts for Agilent Technologies Inc.?
The overall analyst consensus for A is bullish. Out of 26 Wall Street analysts, 10 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $151.00.
How accurate are A stock price projections?
Stock price projections, including those for Agilent Technologies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 6:55 AM UTC